Skip to main content
PRME
NASDAQ Life Sciences

Prime Medicine Prices $125M Underwritten Stock Offering at $4.30 Reference

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.79
Mkt Cap
$707.37M
52W Low
$2.67
52W High
$5.91
52W Position info
42% above low
Off High info
36% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

PRME sits 42% above its 52-week low of $2.67.

Summary

Prime Medicine is raising $125 million (up to $143.75 million with the greenshoe) in an underwritten common stock offering, with the price still blank and a $4.30 November 9 close as the reference. The cash buys runway for Wilson disease and AATD programs at meaningful dilution to existing holders.


Key Events · Financing and Capital Events · PRME

  • $125M Underwritten Offering Launched

    Prime Medicine is offering $125,000,000 of common stock, with a 30-day underwriter option for up to $18,750,000 of additional shares. The public offering price is left blank in this preliminary prospectus supplement.

  • Pricing Reference Set at $4.30

    The filing cites a November 9, 2026 closing price of $4.30 per share as the reference; the actual deal price and discount are not yet stated. At $4.30, the base deal equals about 29.1 million shares ($125M / $4.30) against 180,737,548 shares outstanding as of June 30, 2026 — roughly 16% more shares.

  • Cash Position Down to $61.2M

    Preliminary September 30, 2026 cash, cash equivalents and short-term investments were about $61.2 million, excluding $13.7 million of restricted cash, versus $95.1 million at June 30, 2026. The figures are unaudited and not reviewed by PricewaterhouseCoopers.

  • Proceeds Fund Wilson and AATD Programs

    Net proceeds are earmarked primarily for the Wilson disease and AATD programs and other R&D, with the remainder for working capital, capital expenditures and general corporate purposes.


Analysis · PRME · Life Sciences

Prime Medicine is selling $125 million of common stock in an underwritten deal, with a 30-day option for up to $18.75 million more. The filing sets the reference price at $4.30 (the November 9 close) but leaves the actual public offering price blank, so the final discount is not yet known. This raise is survival capital: cash stood at roughly $61.2 million at September 30, down from $95.1 million at June 30, and the company has previously disclosed a going-concern warning. Proceeds go mainly to the Wilson disease and AATD programs. At the $4.30 reference, the base deal is about 29.1 million shares against 180.7 million outstanding — roughly 16% more shares — and the greenshoe would add about 4.4 million more.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRME was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $707.4M. The 52-week trading range was $2.67 to $5.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRME - Latest Insights

PRME
Nov 10, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $3.76 info
Change: -$0.0403 (-1%) info
Market Cap: $707.37M info
PRME
Nov 10, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.81
Real-time Price: $3.76 info
Change: -$0.0504 (-1%) info
Market Cap: $707.37M info
PRME
Oct 28, 2026, 1:53 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.16
Real-time Price: $3.76 info
Change: -$1.40 (-27%) info
Market Cap: $707.37M info
PRME
Sep 24, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.38
Real-time Price: $3.76 info
Change: +$0.3795 (+11%) info
Market Cap: $707.37M info
PRME
Aug 06, 2026, 8:03 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.05
Real-time Price: $3.76 info
Change: +$0.7097 (+23%) info
Market Cap: $707.37M info